Real-world use of permixon® in benign prostatic hyperplasia - Determining appropriate monotherapy and combination treatment

Advances in Therapy

Volumn 29, Issue 6, 2012, Pages 538-550

  Perry, Richard ^a   Milligan, Gary ^a   Anderson, Peter ^a   Gillon, Andrew ^a   White, Maren ^a  

^a ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Alpha blockers; Appropriate treatment; BPH; Combination therapy; Patient acceptability; Permixon; Phytotherapy; Real world

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION; SPAIN; TREATMENT OUTCOME; URINE FLOW RATE;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FRANCE; HUMANS; MALE; PATIENT PREFERENCE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SOCIOECONOMIC FACTORS; SPAIN;

EID: 84866499207     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0024-x     Document Type: Article

References (22)

1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol. 2006;49:651-8. (Pubitemid 43374725)
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-9. (Pubitemid 14026148)
3. Fourcade R-O, Theret N, Taieb C; on behalf of the BPH USAGE Study Group. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries. BJU Int. 2008;101:1111-8. (Pubitemid 351502660)
4. Kirby RS. The natural history of benign prostatic hyperplasia: What have we learned in the last decade? Urology. 2000;56(Suppl. 1):3-6.
5. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995;332:75-9.
6. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic BPH: A department of Veterans Affairs cooperative study. J Urol. 1998;160:12-6.
7. Netto NR, de Lima ML, Netto MR, D'Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology. 1999;53:314-6. (Pubitemid 29063318)
8. Brown CT, Yap T, Cromwell DA, et al. Self- management for men with lower urinary tract symptoms - A randomized controlled trial. BMJ. 2007;334:25.
9. Madersbachers S, Alivazatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46:547-54. (Pubitemid 39345720)
10. Fourcade R-O, Lacoin F, Rouprêt M, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2011; [Epub ahead of print].
11. Debruyne F, Koch G, Boyle P, et al Grouped'etude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur Urol. 2002;41:497-506. In French.
12. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044.
13. Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004;93:751-6. (Pubitemid 38497023)
14. Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol. 2007;39:879-86. (Pubitemid 47365400)
15. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): A 5-alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate.1999;40:232-41. (Pubitemid 29398049)
16. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol. 2000;164:876-81. (Pubitemid 30637649)
17. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol. 2002;19:426-35.
18. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BPH and inflammation: Pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-55. (Pubitemid 37328630)
19. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-specific programmes - A means to understand. Curr Med Res Opin. 2008;24:3063-72.
20. Hutchinson A, Farmer R, Verhamme K, Berges R, Vela Navarrete R. The efficacy of drugs for treatment of LUTS/BPH: A study in 6 European Countries. Eur Urol. 2007;51:207-16. (Pubitemid 44821521)
21. Emberton M. Medical treatment of benign prostatic hyperplasia: Physician and patient preferences and satisfaction. Int J Clin Pract. 2010;64:1425-35.
22. Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int. 2005;95:15-19. (Pubitemid 350020861)